ReviewPharmacogenomics2014
Pharmacogenomics of antimicrobial agents.
Review in Pharmacogenomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Donor-specific toxicity of copanlisib identified using immune-humanized mice.Cancer immunology, immunotherapy : CII · 2026Article
- La pharmacothérapie en fonction des gènes.Paediatrics & child health · 2023Review
- Gene-based drug therapy in children.Paediatrics & child health · 2023Review
- Improving Antimicrobial Use to Protect the Environment: What Is the Role of Infection Specialists?Antibiotics (Basel, Switzerland) · 2023Article
- Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular?Precision clinical medicine · 2020Article
- The Continuing Threat of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2019Review
- Antibiotic Allergy in Pediatrics.Pediatrics · 2018Review
- Human cytochrome P450 2B6 genetic variability in Botswana: a case of haplotype diversity and convergent phenotypes.Scientific reports · 2018Article
- Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.The Lancet. Infectious diseases · 2018Review
- Recent advances in the understanding of severe cutaneous adverse reactions.The British journal of dermatology · 2017Review
- Discovery of the molecular mechanisms of the novel chalcone-basedSpringerPlus · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Antimicrobial efficacy and toxicity varies between individuals owing to multiple factors. Genetic variants that affect drug-metabolizing enzymes may influence antimicrobial pharmacokinetics and pharmacodynamics, thereby determining efficacy and/or toxicity. In addition, many severe immune-mediated reactions have been associated with HLA class I and class II genes. In the last two decades, understanding of pharmacogenomic factors that influence antimicrobial efficacy and toxicity has rapidly evolved, leading to translational success such as the routine use of HLA-B*57:01 screening to prevent abacavir hypersensitivity reactions. This article examines recent advances in the field of antimicrobial pharmacogenomics that potentially affect treatment efficacy and toxicity, and challenges that exist between pharmacogenomic discovery and translation into clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.